Compare WSE & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSE | BMRN |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 12.3B |
| IPO Year | 2025 | 1999 |
| Metric | WSE | BMRN |
|---|---|---|
| Price | $10.68 | $61.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 28 |
| Target Price | $17.01 | ★ $90.30 |
| AVG Volume (30 Days) | ★ 2.4M | 2.0M |
| Earning Date | 12-01-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $20.63 | $20.01 |
| Revenue Next Year | $16.35 | $14.75 |
| P/E Ratio | ★ N/A | $426.71 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $10.56 | $49.26 |
| 52 Week High | $13.66 | $70.98 |
| Indicator | WSE | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 65.51 |
| Support Level | N/A | $58.03 |
| Resistance Level | $13.37 | $66.95 |
| Average True Range (ATR) | 0.35 | 2.13 |
| MACD | 0.01 | 0.68 |
| Stochastic Oscillator | 8.21 | 83.96 |
Wise is a currency conversion platform that matches, where possible, offsetting currency transactions across borders to reduce costs. The group focuses primarily on private clients and small and midsize enterprises, but it is building out its platform business aimed at providing its services as a backend solution to banks. By operating local accounts in each jurisdiction Wise sends money to or receives money from, this fintech offers faster and cheaper currency transfer services than incumbents (banks). Wise has started to broaden its product offering, issuing its clients debit cards and allowing customers to invest funds in various asset management products.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.